Abarelix
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
ivosidenib
IDH1 inhibitor · Antineoplastic agent
IDH1 inhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
D
FDA category + note
Top interactionssee all 12 →
- AbarelixSevereDatabaseDDInter
- AbirateroneSevereDatabaseDDInter
- AdenosineSevereDatabaseDDInter
- AlfuzosinSevereDatabaseDDInter
Mechanism
Ivosidenib is an orally bioavailable IDH1 inhibitor.
Indications
AML with a susceptible IDH1 mutationcholangiocarcinoma with IDH1 mutations
Side effects
Serious
- differentiation syndrome (can be fatal)
- QTc prolongation
- Guillain-Barré syndrome
Pregnancy & lactation
Pregnancy
D
Drug interactions
Abiraterone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Adenosine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alfuzosin
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amiodarone
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amisulpride
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amitriptyline
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amoxapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Apomorphine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Related guidelines
Other IDH1 inhibitor drugs
Ask House about ivosidenib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team